---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-059392"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2026-05-12T20:10:53+00:00"
generated_at: "2026-05-12T20:58:25.001846+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rezolute Q3 FY2026 net loss $16.2M, cash $120.3M; Phase 3 sunRIZE shows >50% hypoglycemia reduction

## Summary
- Net loss $16.2M vs $18.9M YoY; R&D expense $11.4M, down from $15.3M.
- Cash and investments $120.3M at Mar 31, 2026, down from $167.9M at Jun 30, 2025.
- Phase 3 sunRIZE: ersodetug reduced time in hypoglycemia by >50% (FAS) and 60-80% (PPS) vs placebo.
- FDA Type B meeting in March 2026 acknowledged congenital HI challenges; Rezolute to submit comprehensive datasets.
- Tumor HI Phase 3 upLIFT trial enrolling; topline results expected H2 2026.

## SEC filing metadata
- accession: 0001104659-26-059392
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2026-05-12T20:10:53+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465926059392/0001104659-26-059392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465926059392/tm2614169d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-059392
- JSON: https://secwatch.observer/filing/0001104659-26-059392.json
- Plain text: https://secwatch.observer/filing/0001104659-26-059392.txt

## Key facts
- Earnings Releases
  Rezolute, Inc. reported for the three months ended March 31, 2026 results: net income $16.2 million.
  - Period: for the three months ended March 31, 2026
  - Net income: $16.2 million
  - Result: reported results
  source text: Net loss was $16.2 million for the third quarter of fiscal 2026 compared with a net loss of $18.9 million for the same period a year ago.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509261/000110465926059392/0001104659-26-059392-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.